A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma.

Voss, Martin H; Azad, Arun A; Hansen, Aaron R; Gray, Jhanelle E; Welsh, Sarah J; Song, Xuyang; Kuziora, Michael; Meinecke, Lina; Blando, Jorge; Achour, Ikbel; Wang, Yi; Walcott, Farzana L; Oosting, Sjoukje F

Voss, Martin H; Azad, Arun A; Hansen, Aaron R; Gray, Jhanelle E; Welsh, Sarah J; Song, Xuyang; Kuziora, Michael; Meinecke, Lina; Blando, Jorge; Achour, Ikbel; Wang, Yi; Walcott, Farzana L; Oosting, Sjoukje F.

Afiliación

Voss MH; Memorial Sloan Kettering Cancer Center, New York, New York.
Azad AA; Monash Health, Melbourne, Australia.
Hansen AR; Princess Margaret Cancer Centre, Toronto, Canada.
Gray JE; Moffitt Cancer Center, Tampa, Florida.
Welsh SJ; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Song X; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.
Kuziora M; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland.
Meinecke L; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland.
Blando J; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland.
Achour I; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland.
Wang Y; Early Oncology Biometrics, Oncology R&D, AstraZeneca, Gaithersburg, Maryland.
Walcott FL; Oncology R&D, AstraZeneca, Gaithersburg, Maryland.
Oosting SF; University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Clin Cancer Res ; 28(14): 3032-3041, 2022 07 15.

Article en En | MEDLINE | ID: mdl-35507017

Asunto(s)

Protocolos de Quimioterapia Combinada Antineoplásica; Carcinoma de Células Renales; Neoplasias Renales; Anticuerpos Monoclonales/uso terapéutico; Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos; Carcinoma de Células Renales/tratamiento farmacológico; Humanos; Inhibidores de Puntos de Control Inmunológico; Neoplasias Renales/tratamiento farmacológico; Nivolumab/uso terapéutico; Receptor de Muerte Celular Programada 1/uso terapéutico

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Renales Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google